Comment on "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa"
J Am Acad Dermatol
.
2021 Apr;84(4):e201-e202.
doi: 10.1016/j.jaad.2020.10.095.
Epub 2020 Nov 27.
Authors
Madeline Adelman
1
,
Alexis B Lyons
2
,
Iltefat H Hamzavi
3
Affiliations
1
Wayne State University School of Medicine, Detroit, Michigan.
2
Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.
3
Department of Dermatology, Henry Ford Hospital, Detroit, Michigan. Electronic address: Ihamzav1@hfhs.org.
PMID:
33253840
DOI:
10.1016/j.jaad.2020.10.095
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal / therapeutic use
Hidradenitis Suppurativa* / drug therapy
Humans
Infliximab / therapeutic use
Substances
Antibodies, Monoclonal
Infliximab